(COMTEX) B: BCAM International Secures Worldwide Patent and Technolog
B: BCAM International Secures Worldwide Patent and Technology Rights for Early
Lung Cancer Detection from AccuMed International
MELVILLE, N.Y., Apr 4, 2000 /PRNewswire via COMTEX/ -- BCAM International,
Inc. (OTC Bulletin Board: BCAM), parent company of LungCheck, Inc., announced
today that is has signed a multi-year patent and technology license agreement
with AccuMed International, Inc. (Nasdaq: ACMI). BCAM is actively developing
technology, products and business opportunities in early lung cancer detection,
screening, diagnosis, prognosis and therapeutic monitoring. "Lung cancer,
according to the World Health Organization, has become the most common fatal
malignancy in both men and women with an estimated one million new cases each
year," reported Mr. Strauss, BCAM's Chairman and Chief Executive Officer. Mr.
Strauss added, "This agreement enables BCAM to gain exclusive use of AccuMed's
automated and quantitative microscope technologies, products and patent rights
in the field of early lung cancer detection, and will speed BCAM's efforts to
become the industry leader in the early lung cancer detection business."
Michael Strauss explained "These computer-aided and electronic vision microscope
systems developed by AccuMed are powerful analytical instrument platforms that
enable BCAM to develop and offer morphological, cytochemical, cytogenetic, and
quantitative sputum cytology tests for early lung cancer, including but not
limited to analyses of cellular DNA, Malignancy-Associated Changes (MAC), and
many other genetic or molecular diagnostic tests for early lung cancer. New
objective and quantitative cell analysis-based tests are being developed as a
result of the rapid advances in the field of genomics and molecular pathology
research. BCAM, with its specialized instrument platform technologies it has
just acquired from AccuMed, is uniquely positioned to commercialize these new
and emerging lung cancer tests."
"BCAM is focused on improving patient outcomes through early disease detection
and improved patient management," according to Mr. Strauss. He added that "major
BCAM milestones are anticipated this year in the areas of patient recruitment,
new early lung cancer tests that are scientifically validated, appointment of
leading and internationally recognized medical and scientific advisors, and
additional license agreements with strategic partners in high-volume testing
systems for early lung cancer."
Paul F. Lavallee, AccuMed CEO and Chairman of the Board, stated "We are
delighted to consummate this patent and technology license agreement with BCAM.
We believe that BCAM has the vision, approach, and resources to become
commercially successful and a major contributor to resolving the worldwide
epidemic in lung cancer. AccuMed will be a strategic partner of BCAM in this
endeavor through this technology transfer agreement and AccuMed's equity
participation in BCAM." Furthermore, Mr. Lavallee added, "AccuMed is
particularly encouraged, since this agreement follows on the heels of our
recently announced technology transfer agreement with Ventana Medical Systems
(Nasdaq: VMSI) in the field of analysis of surgical pathology specimens, that
AccuMed's business model of licensing its versatile and advanced imaging systems
to industrial leaders in numerous diverse fields-of-use is being well accepted."
Mr. Lavallee indicated, "The Company anticipates announcing additional major
multi-year, multi-million dollar agreements with other healthcare companies in
the near future."
Except for the historical information contained herein, the matters discussed in
this new release are deemed "forward-looking statement" under federal securities
laws that involve risks and uncertainties. Actual results may differ materially
from those in the forward-looking statements depending on a number of factors,
including, among other things, the ability to maintain long-term relationships
with corporate partners, the ability to bring products to market through the
regulatory approval process, uncertainty of future profitability, financing
requirements, and other factors detailed in BCAM's filing with the Security and
Exchange Commission.
SOURCE BCAM International, Inc.
(C) 2000 PR Newswire. All rights reserved.
prnewswire.com
-0-
CONTACT: Michael Strauss of BCAM International, 516-752-3550
(BCAM ACMI)
KEYWORD: New York
INDUSTRY KEYWORD: MTC
SUBJECT CODE: CON
OTC
*** end of story ***
Nice News!!!!!!!!!!!!!
Mitch |
